Minireviews
Copyright ©The Author(s) 2023.
World J Clin Cases. May 6, 2023; 11(13): 2890-2902
Published online May 6, 2023. doi: 10.12998/wjcc.v11.i13.2890
Table 1 Landmark clinical trials with glucagon-like peptide-1 receptor agonists and the efficacy on diabesity management
Study name
Year
Drug molecule
Mean weight reduction (95%CI/SD)
Mean HbA1c reduction in % (95%CI/SD)
Ref.
Exenatide-113 Clinical Study2004Exenatide 10 mcg twice daily-1.6 kg (SD +/-0.3)-0.86 (SD +/- 0.11) [10]
EXSCEL study2017Exenatide (ER) Once weekly-1.27 kg (-1.40 to -1.13) -0.53 (-0.57 to -0.50)[11]
LEAD 3 (Mono) Trial2009Liraglutide 1.2 mg daily-1.6 kg (-2.43 to -0.88)-1.21 (-1.35 to -1.06) [12]
SUSTAIN 7 Trial2018Dulaglutide 1.5 mg weekly-3.0 kg (SD: 0.27)-1.4 (SD: -0.06) [12]
SUSTAIN 7 Trial2018Semaglutide 1 mg weekly-6.5 kg (SD: -0.28)-1.8 (SD: -0.06)[12]